The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

NCT06192199 | Recruiting

• 1 other identifier: NFEC-2023-501
• Study Type: observational
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmonary embolism group and non pulmonary embolism group. 1. Collect relevant data, including gender, age, primary disease, CTPA imaging and reports, BNP, troponin, electrocardiogram, cardiac ultrasound, PT, APTT, TT, fibrinogen, D-dimer, etc., and analyze demographic data, pulmonary embolism risk grading, APTT/fibrinogen ratio, and determine their cut-off values through statistical analysis of the two groups. 2. Follow up on the APTT/fibrinogen ratio after anticoagulation treatment and bleeding in the pulmonary embolism group.

Conditions

Acute Pulmonary Embolism

Outcome Measures

Primary Outcomes (1)

• Cutoff value of APTT/FIB between patients with and without acute pulmonary embolism

  2024.01-2026.12

Study Arms (2)

Patients with acute pulmonary embolism

Diagnostic Test: 2018 edition of the Guidelines for Diagnosis

Patients without acute pulmonary embolism

Diagnostic Test: 2018 edition of the Guidelines for Diagnosis

Interventions

2018 edition of the Guidelines for Diagnosis DIAGNOSTIC_TEST

According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group

Patients with acute pulmonary embolism; Patients without acute pulmonary embolism

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

From January 1, 2023 to December 30, 2023, the patients were diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination. According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group

You may qualify if:

• Voluntary signing of informed consent form;
• When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender;
• From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination.

You may not qualify if:

• Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction;
• Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation;
• Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement;
• Patients deemed unsuitable for participation in this study by the researchers.

Sponsors & Collaborators

• Nanfang Hospital, Southern Medical University: lead

Study Sites (1)

Nanfang hospital of Southern Medical University

Guangzhou, Guangdong, China

RECRUITING

MeSH Terms

Interventions

Diagnosis

Central Study Contacts

Xintong Huang

CONTACT

8619355230761; 1556807596@qq.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2023
• First Posted: January 5, 2024
• Study Start: January 1, 2018
• Primary Completion: May 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: April 16, 2025

Record last verified: 2025-01

Locations

CN (1)